Mode
Text Size
Log in / Sign up

Metastasis

Part of Metastases

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for metastasis

9 trials tracked for metastasis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 23 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Phase 1 1 Other / NA 2
  1. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 23 cited
  2. Phase 2 A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer Completed
  3. Phase 2 Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer Completed
  4. Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed
  5. Phase 2 Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma Completed
  6. Phase 2 Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment Completed
Show 3 more trials
  1. Phase 1 Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Completed
  2. N/A Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy Completed
  3. N/A Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients. Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.